| Bioactivity | SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an IC50 of 42 μM against nsp13 ssDNA+ ATPase[1]. |
| Target | IC50: 42 μM (nsp13 ssDNA+ ATPase) |
| Name | SARS-CoV-2 nsp13-IN-2 |
| CAS | 522660-61-3 |
| Formula | C20H18N6OS2 |
| Molar Mass | 422.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yazdi AK, et al. Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022 Jul 13. |
SARS-CoV-2 nsp13-IN-2
CAS: 522660-61-3 F: C20H18N6OS2 W: 422.53
SARS-CoV-2 nsp13-IN-2 (Compound C2) is a SARS-CoV-2 non-structural protein 13 (nsp13) small-molecule inhibitor with an I
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.